YS Biopharma Completes Enrollment of 4,500 Subjects in Rabies Vaccine Trial

YS Biopharma (Nasdaq: YS) has completed subject enrollment in a Phase 3 clinical trial of its PIKA rabies vaccine. The trial, which will assess the safety, immunogenicity, and lot-to-lot vaccine consistency, includes 4,500 subjects.

Previous Phase 1 and Phase 2 clinical trials of the PIKA Rabies Vaccine have demonstrated its safety and strong immunogenicity, with the PIKA Rabies Vaccine eliciting a detectable immune response in as little as seven days.

Dr. Muhammad Ahmad, one of the trial’s Principal Investigators, said,  “We hold high hopes that these findings will help establish a new standard in rabies prevention around the world, and we are proud to be taking this significant step into promising new territory.”


The Phase 3 Trial is a randomized, comparator-controlled, double-blind, multi-country and multi-center study that is currently being conducted in Pakistan and the Philippines.

The PIKA Rabies Vaccine, which utilizes YS Biopharma’s proprietary PIKA adjuvant technology, is designed to produce a more robust immune response in an accelerated timespan compared to existing rabies vaccines.

The PIKA Rabies Vaccine has the potential to achieve best-in-class accelerated protection and meet the WHO’s goal of a one-week rabies vaccine regimen to replace the conventional three- or four-week regimens.

Rabies has an almost 100% fatality rate upon emergence of clinical symptoms, claiming the lives of approximately 59,000 individuals in more than 150 countries each year.

About YS Biopharma

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.

About the Author

YS Biopharma Completes Enrollment of 4,500 Subjects in Rabies Vaccine Trial

Catie Corcoran

Biotech Editor